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osting by EAbstract The relationships between chronic liver diseases and trace heavy metal contents in blood
are debatable and have not been understood clearly. The present study was designed to determine
the interaction of IFN a-2b with some trace elements as (Cu, Fe, Mn and Zn) in patients with
chronic hepatitis C, and study the effect of this interaction on the response to therapy. This study
was performed on 42 patients having positive HCV-Ab & HCV-RNA by PCR and treated with
interferon and ribavirin. Besides, 20 healthy subjects served as control. ALT and trace elements
were determined before and after treatment with IFN-a 2b. The results showed that the levels of
Zinc and Manganese in hepatitis C virus (HCV) infected patients’ were decreased compared to
healthy group and this decrement became more after treatment. While the levels of Iron and Copper
increased compared to healthy group and these increment became more after treatment. Serum
ALT levels in the patients after treatment was statistically signiﬁcant decrease (p< 0.05) when com-
pared to its level before treatment.
Conclusion: Our ﬁndings imply that the levels of trace elements (manganese, iron, copper, zinc,
and Cu: Zn ratios) might serve as biochemical parameters with a predictive value for the responsive-
ness of patients to interferon/ribavirin therapy as there were changes in the levels of some trace.A. Mohammed).
iﬁc Research & Technology.




82 M.A. Mohammed et al.elements (Zn and Mn) between responder and non-responder patients. So trace element abnormal-
ities may reﬂect the condition of liver dysfunction.
ª 2012 Academy of Scientific Research & Technology. Production and hosting by Elsevier B.V.
All rights reserved.1. Introduction
Hepatitis C virus (HCV) infections are of particular impor-
tance owing to its high frequency of chronicity, leading to he-
patic failure, cirrhosis and hepatocellular carcinoma. It affects
almost 3% of the world’s population with a morbidity and
mortality rates that are second to HIV among the emerging
infections. The highest estimated prevalence of HCV has been
reported in Egypt with 11–14% of the population chronically
infected with the virus [8]. This is ten times greater than any
other country in the world [6].
Various trace elements are responsible for many biochemi-
cal, immunological, and physiological activities. Since the
metabolism of trace elements takes place in the liver, the con-
centration of each trace element may be varied with different
types of liver disease [25]. Essential micronutrients are involved
in many metabolic pathways in the liver; such as enzymatic
functions, protein synthesis, oxidative reactions and anti-oxi-
dant defence, immunological competence, interferon therapy
response regulations and alterations of the virus genomes [16].
The concentration of each trace element varies with differ-
ent types of liver diseases because these elements may have a
direct hepatic toxicity or may be decreased as a consequence
of the impaired liver function. Among these trace elements,
zinc (Zn) is a micronutrient inﬂuencing growth and affecting
the development and integrity of the immune system. It has
a critical role for the function of over 300 enzymes. Further-
more, it plays an important role in function of the liver [1].
The liver is the main iron storage organ and it plays a fun-
damental role in iron metabolism. The iron transport protein,
transferrin, and the major iron storage protein, ferritin, are
synthesized in the liver [28]. There is a key link between iron
metabolism and pathophysiology of viral hepatitis. Increase
in iron stores (increase in serum ferritin and transferrin iron
saturation) leads to increased response to HCV infection,
and progression of chronic hepatitis C. It was found that liver
impairment in HCV related chronic liver disease is the main
cause of blood decrease in selenium and zinc, independently
of the nutritional status, whereas the associated malnutrition
affects the ferrous levels only [13].
Iron and zinc may improve the response of chronic hepati-
tis C patients to interferon treatment; moreover viral factors
may affect the outcome of the therapy. Copper acts as a cofac-
tor against hepatic ﬁbrosis in chronic liver diseases, particu-
larly in the biosynthesis of collagen. As the disease
progresses from chronic hepatitis to liver cirrhosis, copper lev-
els increase [31].
HCV infection frequently leads to chronic hepatitis with
increasing risk of developing liver cirrhosis and HCC. Inter-
feron with or without ribavirin is the only drug with proven
efﬁcacy in treating chronic HCV infections. Unfortunately,
these therapeutic models maintain the rate of sustained viro-
logic response (SVR) to approximately 10–40% [11]
The relationship between chronic hepatitis and trace
elements has not been understood clearly. So the aim of thepresent study was to compare the alterations in serum levels
of the trace elements, including zinc, iron, manganese and cop-
per in Egyptian patients with chronic viral hepatitis C, and
also to detect the response of patients to the interferon
(IFN-a2b) therapy.
2. Subjects and methods
2.1. Subjects
This study was conducted on 42 Egyptian patients with
chronic hepatitis C virus infection, who were selected from
the National Hepatology and Tropical Medicine Research
Institute in Cairo. They were diagnosed according to the fol-
lowing criteria; elevated serum alanine aminotransferase
(ALT) above the upper limit of normal (40 IU) on two occa-
sions during the preceding six months, anti-HCV positive
antibody status, positive polymerase chain reaction for HCV
RNA and positive liver biopsy (histopathological changes)
for chronic hepatitis C performed within the preceding year
with no signs of cirrhosis. Patients were excluded from this
study if they had previous IFN-a therapy or any other liver
diseases. In addition, 20 healthy volunteers in the same so-
cio-economic status served as a control group.
Fasting blood samples were taken from all subjects (two
blood samples from each patient before and after therapy) in
accordance with standard procedure; 6–8 mL of blood was col-
lected from the vein and protected in evacuated tubes without
adding any anticoagulant agent. The samples were left stand-
ing for one hour; sera were separated at 3000 rpm centrifuga-
tion for 10 min and preserved at 20 C. This study was
approved by the Institutional Ethical Committee.
2.2. Protocol of therapy
The patients were treated with Interferon Alpha 2b (Interon-
Scherring, USA) and Ribavirin. An injection of 3 million units
of IFN-a2b was administered once per week for 24 weeks
(6 months). Ribavirin was administered according to body
weight (10 mg/kg/day) with the average dose ranging from
800 to 1000 mg/day.
2.3. All participants were subjected to the following
(1) Complete medical history for all patients; they were
sero-positive for antibody to HCV (EIA 2, Abbott Lab-
oratory). Positivity for HCV RNA by PCR using Cobas
Amplicor HCV assay Version I (Roche diagnostic)
(2) Determination of serum alanine transaminase (ALT) by
colorimetric method and the reagents were obtained
from Bayer Diagnostics (France) [2].
(3) Atomic absorption spectrophotometery: This method
was done according to Price [24]. Determination of Zinc,
Copper, Iron and Manganese by atomic absorption
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same dilution, but at different wave-lengths. The
absorption for each ion (Cu, Fe, Mn and Zn) markedly
free from interference effects and levels were estimated
in the serum.3. Statistical analysis
Data were presented as ranges and means ± SD. The unpaired
student ‘‘t ’’ test was used for comparing the means of both
groups. Pearson correlation test was used to correlate between
different variables among the studied groups [33]. Computer
based statistical package for social sciences (SPSS) version 16
(SPSS Inc., Chicago, IL, USA). Signiﬁcance was assigned for
p values (<0.05).
4. Results
Fig. 1 showed the histopathological diagnosis of the patients
with chronic hepatitis C virus.
Table 1 showed the demographic data of the patients and
statistical analysis of serum Copper, Iron, Manganese, Zinc,
Zinc/Manganese, Copper/Zinc and ALT in the patients before
& after treatment in comparison to the mean values of their
corresponding control group.
The selected study group comprised 42 patients with HCV
that included 25 males and 17 females, their age ranged be-
tween 16 and 56 years (mean of 37 ± 9.3 years). The number
of patients after treatment were 40 patients due to loss of
two patients (they did not complete their therapy). The control
group comprised 20 healthy volunteers which were 12 males
and eight females, their age ranged between 15 and 60 (mean
of 38 ± 8.7) years.
- Iron: The mean value ± S.D for Iron levels were
(105.1 ± 6.5), (171.3 ± 10.71) and (190.4 ± 10.42) in control
group, before and after treatment groups, respectively.Figure 1 Section examined from the specimens received revealed
liver core with preserved architure, hepatocytes arranged in the
thin plates with mild steatosis, mild ballooning. There is minimal
spotty necrosis. Portal areas revealed mild lymphocytic inﬁltrate
and mild interface activity, no ﬁbrosis, no granulomatous reaction
and no malignancy. (ISHAK, stage 0/6).- Copper: The mean value ± S.D for Copper levels were
(80.0 ± 1.57), (41.3 ± 2.40) and (26.4 ± 1.18) in control
group, before and after treatment groups, respectively.
- Manganese: In control group the mean value ± S.D for
Manganese levels was (16.3 ± 0.49) whereas these values were
(18.20 ± 1.20) and (31.90 ± 1.53) before and after treatment
groups, respectively.
- Zinc: In control group the mean value ± S.D for Zinc levels
was (83.6 ± 1.96) whereas these values were (71.1 ± 3.38) and
(50.5 ± 3.43) before and after treatment groups, respectively.
- Zinc/Manganese: In control group the mean value ± S.D
for Zinc/Manganese levels was (5.2 ± 0.19) whereas these val-
ues were (4.5 ± 0.33) and (1.9 ± 0.21) before and after treat-
ment groups, respectively.
- Copper/Zinc: In control group the mean value ± S.D for
Copper/Zinc levels was (0.97 ± 0.02) whereas these values
were (0.63 ± 0.05) and (0.61 ± 0.06) before and after treat-
ment groups, respectively.
- Alanine aminotransferase (ALT): The mean value ± S.D
for ALT levels were (21.3 ± 0.93), (57.3 ± 3.1) and (38.8 ± 3.2)
in control group, before and after treatment groups, respectively.
- As regards to the statistical signiﬁcant of the trace elements
in the patients the results showed that serum iron concentra-
tion was signiﬁcant increased (p< 0.05), Cu, Zn and Cu/Zn
were signiﬁcant decrease (p< 0.05), when compared to con-
trols. Also there was statistically signiﬁcant increase in Fe
and Mn concentrations, but statistically signiﬁcant decrease
in Cu and Zn concentrations when comparing both pre and
post treatment results (p< 0.05). ALT levels in serum of
HCV infected patients before treatment was signiﬁcant
increased compared to control group; and after treatment
there was signiﬁcant decrease in its levels when compared to
its level before treatment but still high than the control group.
Table 2 showed statistically non-signiﬁcant correlation be-
tween ALT versus different trace elements before therapy by
using correlation co-efﬁcient test (Pearson-r) test p> 0.05.
(There was no correlation between the ALT and each of Fe,
Cu, Zn, Cu/Zn, Mn, and Zn/Mn before treatment, (r= 0.12,
0.11, 0.05, 0.19, 0.03, 0.11, respectively, p> 0.05).
Table 3 showed statistically signiﬁcant positive correlation
between ALT and Fe after treatment [r= 0.32, p< 0.05]
but there was no correlation between ALT and Cu, Zn, Cu/
Zn, Mn, Zn/Mn after IFN treatment, (r= 0.014, 0.07,
0.25, 0.14, 0.26, respectively, p> 0.05).
Table 4 Showed the comparison between responder and
non-responders patients as regards Fe, Cu, Zn Mn (ng/dl)
Cu/Zn and Zn/Mn after treatment, serum level of Zn was
signiﬁcantly high among responders compared to the non-
responders patients while serum level of Mn was signiﬁcantly
low among responders compared to the non-responders pa-
tients (p< 0.01). On the other hand there is no signiﬁcant dif-
ference in both groups as regards other trace elements.
5. Discussion
HCV infection frequently leads to chronic hepatitis with
increasing risk of developing liver cirrhosis and HCC. The
Table 1 Concentration of trace elements and its statistical signiﬁcance in control group and HCV patients before and after interferon
treatment.
Parameters Control I (20) Before treat. II (42) After treat. III (40) p value
Age (years)
Range 15–60 16–56 16–56
Mean ± S.D 38 ± 8.7 37 ± 9.3 36 ± 8.9
Male 12 25 23
Female 8 17 17
Cu (ng/dl)
Range 74.4–101.2 17–76 15–42 I:II < 0.05*
Mean ± S.D 80.0 ± 1.57 41.3 ± 2.40 26.4 ± 1.18 II:III < 0.05*
Fe (ng/dl)
Range 65.8–145.8 103–347 111–353 I:II < 0.05*
Mean ± S.D 105.1 ± 6.5 171.3 ± 10.71 190.4 ± 10.42 II:III < 0.05*
Mn (ng/dl)
Range 13.4–18.9 14–37 20–56 I:II > 0.05
Mean ± S.D 16.3 ± 0.49 18.2 ± 1.2 31.9 ± 1.53 II:III < 0.05*
Zn (ng/dl)
Range 71.2–99.8 34–105 17–90 I:II < 0.05*
Mean ± S.D 83.6 ± 1.96 71.1 ± 3.8 50.5 ± 3.43 II:III < 0.05*
Zn/Mn
Range 4.0–6.7891 2.5–6.5 0.6–3.2 I:II > 0.05
Mean ± S.D 5. 2 ± 0.19 4.5 ± 0.33 1.9 ± 0.21 II:III < 0.05*
Cu/Zn
Range 0.845–0.995 0.58–0.68 0.56–0.66 I:II < 0.05*
Mean ± S.D 0.97 ± 0.02 0.63 ± 0.05 0.61 ± 0.06 II:III > 0.05
ALT (IU/L)
Range 12–32 35–121 26–117 I:II < 0.05*
Mean ± S.D 21.3 ± 0.93 57.3 ± 3.1 38.8 ± 3.2 II:III < 0.05*
* p< 0.05 considered signiﬁcant.
Table 2 Correlation between ALT (IU/L) and Fe, Cu, Zn,
Mn (ng/dl), Cu/Zn and Zn/Mn before treatment.
Variables ALT (IU/L)
r p
Fe (ng/dl) 0.12 >0.05
Cu (ng/dl) 0.11 >0.05
Zn (ng/dl) 0.05 >0.05
Cu/Zn 0.19 >0.05
Mn (ng/dl) 0.03 >0.05
Zn/Mn 0.11 >0.05
Table 3 Correlation between ALT (IU/L) and Fe, Cu, Zn Mn
(ng/dl), Cu/Zn and Zn/Mn after treatment.
Variables ALT (IU/L)
r p
Fe (ng/dl) 0.32 <0.05*
Cu (ng/dl) 0.014 >0.05
Zn (ng/dl) 0.07 >0.05
Cu/Zn 0.25 >0.05
Mn (ng/dl) 0.14 >0.05
Zn/Mn 0.26 >0.05
* p< 0.05 signiﬁcant.
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liver disease in case of deﬁciency, imbalance, or toxicity [22].
Clinical studies reported that hepatitis C virus (HCV) related
chronic liver disease patients at different stages of liver damage
have impaired metabolism of trace elements [25].
The purpose of study was to investigate blood level of trace
elements (Cu, Fe, Zn and Mn) in the patients with chronic hep-
atitis C before and after treatment by IFN a-2b, and to ﬁnd the
relationship between the changes of these levels.
Serum alanine aminotransferase (ALT) levels is an impor-
tant marker for the management of chronic hepatitis C. ALT
levels in serum of HCV infected patients before and after treat-
ment was statistically signiﬁcant decrease (p< 0.05).This is
consistent with the results obtained by Kajiwara, who reported
that biweekly low-dosage peg-interferon a-2a therapy for
chronic hepatitis C is effective for reducing the serum levels
of ALT and AFP and may reduce hepatocarcinogenesis in
patients with liver cirrhosis and in the elderly individuals [14].
Zinc has an antioxidant, anti-inﬂammatory activities and
induces metallothionein which has radical scavenging and
immunomodulatory effects [30]. The results of present study
showed that Zn levels in serum of HCV infected patients be-
fore treatment were statistically signiﬁcant decreased, while
after treatments they were highly statistically signiﬁcant de-
creased when compared with control group. This was in accor-
dance with the result of Qasim who compared serum copper
and zinc concentration in patients suffering from chronic
Table 4 Comparison between responder and non-responders cases as regards Fe, Cu, Zn Mn (ng/dl) Cu/Zn
and Zn/Mn after treatment.
Variables Non responders N= 11 Responders N= 29 p
Fe (ng/dl) 191 ± 70.9 187.3 ± 58 >0.05
Cu (ng/dl) 24.8 ± 7.3 26.1 ± 6.9 >0.05
Zn (ng/dl) 37.5 ± 12.5 56.4 ± 20.6 <0.05*
Cu/Zn 0.72 ± 0.31 0.56 ± 0.42 >0.05
Mn (ng/dl) 37.5 ± 11.3 29.3 ± 6.4 <0.05*
Zn/Mn 1.6 ± 1.8 1.9 ± 0.9 >0.05
* p< 0.05 considered signiﬁcant.
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serum copper concentration is higher in chronic hepatitis C pa-
tients as compared to healthy control groups, while the serum
zinc concentrations were signiﬁcantly lower in chronic hepati-
tis C patients than healthy control groups [25]. Marchesini
found that the Zinc deﬁciency is common in patients who have
advanced cirrhosis when there is liver damage [19].
Nagame reported that, the patients responded completely
to interferon therapy were found to have a higher serum Zn/
Cu ratio than the patients who did not respond to interferon.
Therefore, they advised Zn administration as an adjunct to
interferon therapy in chronic HCV infections [21], they pro-
posed that Zn increased antiviral effect and in turns response
to interferon therapy. However our results are not parallel
with these ﬁndings as serum Zn levels were similar between
the patients and controls, and did not changed by interferon
treatment in HCV.
The results of present study showed that, the Fe levels in
serum of HCV infected patients before and after treatment
were highly statistically signiﬁcant increase when compared
to control group. These results were in agreement with Sikors-
ka and Metwally who reported that, there is an obvious in-
crease of iron contents in the serum of these patients [29,20].
The effectiveness of interferon is less and the patients be-
come non responders to treatment (i.e. the interferon non
responders) when iron increased in blood. This means that iron
depletion help interferon therapy to achieve sustained vitro-
logic response in this individual [3].
There have been various controversial reports on copper
level in serum.Nagasue et al. reported signiﬁcant change of cop-
per in the course of acute or post-hepatitic infections [26]. While
Qasim found that serum copper concentration is higher in
chronic hepatitis C patients as compared to healthy control
group and the serum zinc concentrations were signiﬁcantly low-
er in chronic hepatitis C patients than healthy control group
[25]. To contradict these results we have found in this study low-
er copper content in serum of HCV infected patients before and
after treatment which were highly statistically signiﬁcant de-
crease when compared with control group. This result was in
accordance with the result of Halliwell &Gutteridgein which re-
ported that copper excess affect liver ﬁbro-genesis by promoting
necrosis or enhancement of lysyl-oxidase activity [9].
Our results showed that Cu/Zn ratios in serum of HCV in-
fected patients before and after treatment were statistically sig-
niﬁcant decrease, when compared with control group. This is
in accordance with the result of Lin who found that Cu/Zn
ratios might serve as biomarkers for the increased severity of
viral hepatic damage. On the other hand compared with cop-
per, the decrease of serum zinc is more closely related with
the development of disease from the view of the ratio of copperto zinc (the normal value is 1). The ratio increased gradually in
chronic hepatitis infection [18].
In a study done by Iclal, they reported that increased Cu
levels were encountered in chronic viral hepatitis. Copper lev-
els were not changed with interferon treatment. Changes in the
content of microelements may depend on the severity of the
underlying disease [12]. Some of the trace elements such as
Cu function like a co-factor against hepatic ﬁbrosis in chronic
liver disease, particularly in the biosynthesis of collagen. As the
disease progresses from chronic hepatitis to liver cirrhosis, ser-
um calcium, magnesium, phosphorus and Zn concentrations
decrease while the Cu concentration increases [17].
Kalkan studied serum trace elements, including copper in
sera of patients with viral hepatitis (A, B, C, D and E) cases
and the controls. They have shown elevation in copper levels
and have suggested that this probably resulted from defense
strategies of organism and induced by hormone like sub-
stances. The role of copper during hepatitis virus infection
needs further investigations [15].
Pramoolsinsap founded that serum Zn levels decreased sig-
niﬁcantly in patients with chronic active hepatitis, cirrhosis,
and hepatocellular carcinoma and Cu levels increased signiﬁ-
cantly only in patients with hepatocellular carcinoma [23].
While Cesur et al. compared serum zinc and copper concentra-
tions in patient chronic hepatitis C (n= 17) and control
healthy (n= 17) they did not ﬁnd any statistically signiﬁcant
difference between healthy individual and patient with chronic
hepatitis C.They concluded that, serum trace element concen-
trations did not show statistical alterations in patients with
chronic hepatitis C compared to healthy subjects [4].
The results of present study showed that, the Mn levels in
serum of HCV infected patients before treatment were not sta-
tistically signiﬁcant increase (p> 0.05), while after treatment
were highly statistically signiﬁcant increased (p< 0.01) when
compared with control group. This is in accordance with the re-
sult of Herber et al. who reported thatManganese neurotoxicity
developed in a highly exposed worker after asymptomatic and
moderate hepatic dysfunction from hepatitis C infection. Anti-
viral therapy was accompanied by resolution of increased blood
manganese levels and neurologic improvement. Even asymp-
tomatic hepatic dysfunction may impair manganese clearance
and place highly exposed persons at risk for toxicity [27].
Intestinal absorption of both iron and manganese are in-
creased in iron deﬁciency. Iron deﬁciencymay therefore increase
the susceptibility to manganese neurotoxicity. The log of eryth-
rocyte manganese concentration was inversely correlated
with all measures of iron status. These ﬁndings conﬁrm the
association of manganese with the development of the pallidal
hyper intensity in patients with liver disease. Increased excretion
of zinc and iron in cirrhosis leads to decreased excretion of
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mended that patients with chronic liver disease should avoid
manganese supplements without concurrent iron supplementa-
tion [10].
On the other hand Suzuki et al. found that patientswith acute
hepatitis had serum low manganese levels and these abnormal-
ities may reﬂect such pathological conditions as liver dysfunc-
tion cholestasis, hepatic ﬁbrosis or liver regeneration [31].
The results of this study showed Zn/Mn ratios in serum of
HCV infected patients before and after treatment were statisti-
cally non-signiﬁcant, when compared with control group. This
is in accordance with the result of Fabris et al. who found that
in hepatic HCV, Fe, Zn levels and Zn/Mn ratio reﬂects the
degree of current hepatic inﬂammation and necrosis [7].
Kalkan et al. and Czuczejko et al. also reported that there
were decrease in levels of Zn and Cu and increase in levels of
Fe and Mn levels in sera of hepatitis cases [15,5].
Therapy with interferon a-2b can lead to even lower levels
of Zn and copper in blood serum, since the response to inter-
feron a-2b mono therapy among patients with chronic hepati-
tis C is less than 20% [32].
Nutritional status of zinc inﬂuences the effect of IFN on
hepatitis C patients. This fact is supported by the study of
Nagame et al. who observed that basal zinc levels in the serum
are signiﬁcantly lower in chronic hepatitis C patients. Admin-
istration of IFN-a to hepatitis C patients augments serum zinc
reductions up to 40% in 8 h. Serum zinc level and zinc/copper
ratio are higher in complete responders than in non-responders
to IFN therapy at each time point [21].
Zinc (Zn) has various signiﬁcant roles in physiological func-
tions of the liver. Furthermore, it has been reported that the
administrationofzinchasan important role inpharmacotherapy
of viral hepatitis [1]. In the present study, serum Zn was highly
signiﬁcantly increased in chronic HCV patient’s responder to
interferon therapy thannon-responder patients, before andafter
treatment.These resultswasnot inaccordance toWang-Shenget
al. study in which they reported that, serum zinc levels were sig-
niﬁcantly lower in chronic hepatitis C patients than in healthy
controls and further depressed by IFN/ribavirin treatment [16].
6. Conclusion
Trace element abnormalities may reﬂect the condition of liver
dysfunction. These results suggested that liver functional
impairment may alter the metabolism of trace elements, in par-
ticular, zinc and copper. Our ﬁndings imply that the levels of
trace elements (manganese, iron, copper, zinc, and Cu: Zn
ratio) might serve as biochemical parameters with a predictive
value for the responsiveness of patients to interferon/ribavirin
therapy as there were changes in the levels of trace elements be-
tween responder and non-responder patients. We recommend
further studies to know if some trace elements have synergistic
effect with interferon therapy or not.
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